Tag:

oral

Carezen Develops Obesity Treatment Beyond Dietary Supplements

by Dr. Michael Lee – Health Editor August 26, 2025

written by Dr. Michael Lee – Health Editor

Caregen Pursues‌ Domestic Obesity Drug Approval After Overseas‌ Coglutide Success

SEOUL, SOUTH KOREA -⁣ Caregen is developing ⁣an obesity treatment intended for teh domestic ‍market, a ⁢move prompted by regulatory hurdles ‍preventing approval of its coglutide product⁣ as a health functional food in South korea. Company officials believe success in⁤ developing a dedicated obesity drug⁣ will ‍pave the⁢ way for domestic licensing.

“The obesity treatment that is currently being developed is actually much better than the coglu tide,” ‍stated Chung,⁤ a company⁢ representative.

caregen has already secured export contracts for coglutide with companies in Canada, Mexico, and Thailand, totaling 30.5 billion⁤ won this month. The company attributes the difficulty in obtaining domestic⁢ approval to the fact that⁣ regulators currently do not recognize peptides as acceptable raw materials for ⁤health functional foods.

“If you succeed in developing obesity drugs within the company, we⁣ expect domestic permission to have no ‌problem,” Chung added.

Clinical trials‍ conducted in India on 100 obese patients demonstrated promising results for coglutide. Participants ⁤taking 100mg of coglutide daily for 12 weeks experienced an⁣ average weight loss of 10.78%, alongside significant improvements in‌ body ‌mass index (BMI), waist-hip ratio, and⁣ visceral fat levels. Importantly, the company reported ⁢minimal muscle loss among ⁤trial participants.

Caregen is ‌currently conducting a second clinical trial involving 200 adults, specifically targeting individuals with “dry obesity” – characterized by high ‌body fat percentage despite a normal weight.This expanded trial ⁣aims to position the‌ product⁤ as a daily weight management solution⁤ applicable to a broader ‌population beyond those clinically‍ defined as obese.

“We are ⁢conducting 200 additional clinical‌ trials after 100 people, but there‍ have been no side effects yet,”⁣ chung confirmed.

The company ⁣expressed confidence in ⁢the future development ‌of⁤ its obesity treatment, citing the⁣ positive‌ outcomes observed with ‌coglutide. “We are also convinced of successful development of obesity treatment based⁣ on ‍cogluide achievements,” Chung⁢ said.

By Bang Tae‌ -sik, reporter kiseat@dealsite.co.kr

August 26, 2025 0 comments

Technology

Young Man in Simalungun Faces Stage 3B Rectal Cancer: A Heartbreaking Health Battle Unfolds

by Chief editor of world-today-news.com March 1, 2025

written by Chief editor of world-today-news.com

North Sumatra Man’s Years-Long Battle with Stage 3B Rectal Cancer

TIGA DOLOK, north Sumatra – Fourten Ary admaja Sinaga, a 28-year-old resident of Tiga Dolok, Simalungun, North Sumatra, is fighting stage 3B Stadium Rectum Cancer. Diagnosed in 2020 at just 23 years old, his journey has involved multiple treatments and health complications.His wife, Desika Sitorus, has been his constant support, navigating the complexities of his illness and treatment options. The initial symptoms began shortly after their marriage, marking the start of a challenging chapter in their lives.

Desika Sitorus, Ary’s wife, recalls the early signs of the illness. After two weeks of marriage, the husband experienced problems during defecation (BAB), she told AFP, detailing the onset of the distressing symptoms. the couple’s life was quickly consumed by the realities of cancer treatment and its impact on their daily lives.

Early Symptoms and Initial Diagnosis

The early symptoms where alarming and disruptive. Desika described the initial signs,stating,The husband’s chapter came out a little but continued to be accompanied by blood and yellow liquid sticking to the stool. Untill the long time the stool came out without being held back to use pampers while working becuase the eek continued to come out. This rapid deterioration prompted them to seek medical attention.

Adding to their concerns, Ary experienced dramatic and unexplained weight loss. His weight plummeted from 72 kg to 40 kg, despite maintaining a normal diet. This drastic change, coupled with the other symptoms, underscored the severity of his condition. Desika explained that due to his worsening condition, thay decided to seek medical help at Merauke Hospital in Papua.

The diagnostic process was lengthy and stressful. Biopsy waiting for a month to read it turns out that a malignant tumor in the rectum due to the limited treatment at Merauke Digstive Doctor Merauke suggested treatment at a hospital that had a hospital in big cities, Desika said, highlighting the limitations of local medical facilities and the need for specialized care. The wait for the biopsy results added to their anxiety and uncertainty.

Referrals and Initial Treatments

The couple then faced the challenge of finding appropriate medical care. What was finally referred to Medan to my hometown. Then we returned home to the three Dolok in 2021 because the husband’s condition was very alarming, she continued, illustrating the urgency and difficulty of navigating the healthcare system. The referral process was a critical step in getting Ary the specialized treatment he needed.

Initially, Ary sought traditional medicine in his village, but thes efforts proved unsuccessful. His condition continued to deteriorate, leading to further medical interventions. He was then rushed to the Harapan Hospital, Siantar, and later referred to Mitra Sejati Hospital. There, he underwent a major operation to create a stoma and another biopsy was performed. Following this, he was referred to Adam Malik Hospital in Medan for chemotherapy.

desika recounted the series of referrals, stating, then after a month referred to Adam Malik General Hospital for chemotherapy. This marked the beginning of an extensive and arduous treatment regimen. The chemotherapy was a significant step in attempting to combat the cancer.

Chemotherapy and Radiotherapy

Ary underwent an intensive chemotherapy regimen, consisting of eight cycles every two weeks over six months. Despite these efforts, evaluations revealed that the malignant tumor remained. Undeterred, the medical team continued with a second chemotherapy regimen for another six months, maintaining the same cycle frequency. Sadly, this also failed to yield positive results.

The next phase of treatment involved radiotherapy, with Ary undergoing 25 sessions over more than a month. However, the tumor persisted, showing no signs of receding. Desika also mentioned that her husband underwent 24 oral chemotherapy sessions, but these, too, did not produce significant improvements. The third regimen lasted almost eight months but did not provide the expected results due to tumor adhesions. The doctors then added 12 more chemotherapy cycles, which are still ongoing.

Additional Health Complications

Initially, Ary was able to continue working as an online motorcycle taxi driver when he wasn’t undergoing chemotherapy. However,his health took a turn for the worse in early 2024. early in 2024 the husband worsened due to kidney stones and tuberculosis, it turned out that when it was operated on the 7th month of 2024, his kidney stones were appointed to have spread to the bladder and when inspected by the tuberculosis had also spread to the lungs of the cancer starting from there her husband was getting worse until now which made him not working anymore, Desika explained, highlighting the cascade of health issues that have further intricate his condition.

The cumulative effect of these ailments has significantly impacted Ary’s quality of life. Now the husband’s condition has been very alarming recently, CT scan again as there is a narrowing in the Ambung that is still being sought knowing what is the swelling of the kidneys and liver that for the husband does not want to eat anymore difficult to walk and always in pain, she added, painting a grim picture of his current state. The additional health problems have made his battle even more challenging.

Genetic Predisposition

Desika believes that genetic factors may have contributed to Ary’s rectal cancer. She revealed that Ary’s father had gastric cancer and eventually passed away from the disease.This family history suggests a potential genetic predisposition to cancer within the family.

Conclusion

Fourten Ary admaja Sinaga’s battle with Stage 3B Stadium Rectum Cancer is a testament to the challenges faced by individuals battling serious illnesses. His journey, marked by numerous treatments, complications, and unwavering support from his wife, Desika Sitorus, underscores the importance of early detection, extensive medical care, and continued research in the fight against cancer. As Ary continues his treatment, his story serves as a reminder of the strength and resilience of patients and their families in the face of adversity.

The Grueling Battle Against Rectal Cancer: A Medical Expert Weighs In

Rectal cancer, while less common than colon cancer, presents unique challenges in diagnosis and treatment. Dr. Anya Sharma, a leading oncologist specializing in colorectal cancers, provides insights into the complexities of this disease.

Senior Editor (SE): Dr. Sharma, the case of Fourten Ary Admaja Sinaga highlights a protracted struggle with Stage 3B rectal cancer. What are some of the specific challenges associated with this advanced stage of the disease?

Dr. Sharma (DS): Stage 3B rectal cancer signifies that the cancer has spread to nearby lymph nodes, making complete surgical removal more challenging. This advanced stage frequently enough necessitates a multimodal approach, combining surgery, chemotherapy, and radiation therapy.The proximity of the rectum to critical structures like the bladder and nerves adds critically significant complexity to surgical procedures, increasing the risk of complications like incontinence or sexual dysfunction. Treatment decisions are highly individualized, considering the patient’s overall health, tumor characteristics, and response to therapy during each phase.

SE: The article details Mr. Sinaga’s experience with multiple treatment regimens, including chemotherapy and radiotherapy, yet the tumor persisted. Why might these treatments not always be effective in cases like his?

DS: Sadly,not all cancers respond equally well to standard treatments. Tumor heterogeneity,meaning the cancer cells themselves are diverse in their genetic makeup and behaviour,contributes to treatment resistance. Some cancerous cells might be intrinsically resistant to chemotherapy drugs or radiation, allowing them to survive and proliferate. The presence of tumor adhesions, as mentioned in Mr. Sinaga’s case, can further hamper the effectiveness of treatment.The adhesions essentially bind the tumor to surrounding tissues,making it arduous to surgically remove fully or for chemotherapy drugs to penetrate effectively to eradicate all cancer cells. Moreover, advanced stages frequently enough involve microscopic cancer spread that’s undetectable, requiring long and consistent treatments to manage.

SE: Mr. Sinaga experienced significant weight loss, a common symptom frequently enough linked to cancer. What are the mechanisms by which cancer causes weight loss, and what should individuals be aware of?

DS: Unintentional weight loss in cancer patients is a complex problem with multiple potential causes. Cancer cells compete with healthy cells for nutrient resources, leading to malnourishment. This is often exacerbated by the side effects of treatments like chemotherapy and radiotherapy, reducing appetite and causing digestive issues. Furthermore, the production of inflammation-promoting substances by the tumor, coupled with metabolic changes induced by the disease, can contribute to significant weight loss. Individuals should be vigilant about any unexplained weight loss, especially when accompanied by other symptoms like fatigue, changes in bowel habits, or persistent abdominal discomfort. prompt medical evaluation is crucial to determine the underlying cause.

SE: The article mentions the potential impact of genetics. How significant is a family history of cancer, such as Mr. Sinaga’s father’s history of gastric cancer, in assessing an individual’s risk factors for rectal cancer?

DS: A family history of cancer, notably colorectal cancers, significantly increases the risk of developing the disease.While not a guarantee of disease occurrence, it highlights a genetic predisposition. Genetic testing might reveal specific gene mutations that suggest an increased likelihood of developing certain cancers. Knowing your family medical history is vital as a preventative strategy. Early detection screening—colonoscopies and other relevant screenings—should begin earlier and more frequently with genetic predispositions.

SE: What are some key takeaways for individuals seeking preventive measures against colorectal cancers?

DS:

Maintain a healthy lifestyle: A diet rich in fruits, vegetables, and fiber, coupled with regular exercise, is vital.
Limit red and processed meat consumption: These are associated with increased risk.
Avoid smoking and excessive alcohol consumption: Both increase cancer risks.
Follow recommended screening guidelines: Beginning at age 45 (or earlier if family history exists).
Know your family medical history: Discuss any cancer histories with your physician to provide a extensive overview of personal risk.

SE: What is the outlook for patients with stage 3B rectal cancer?

DS: The prognosis for stage 3B rectal cancer varies, depending on several individual factors. Advances in treatment strategies, including improved chemotherapy regimens and targeted therapies, have improved outcomes significantly. While it remains a serious condition,early detection and treatment adherence are crucial for better long-term survival rates. Regular follow-up care is also essential in detecting any recurrence after primary treatment. The data in this interview is for general knowledge and should not substitute professional medical advice.

In closing,Mr. Sinaga’s story,while challenging,highlights the importance of early detection,advanced treatment options,and the unwavering support systems that patients need during such battles.The resilience of individuals and families facing this disease is truly inspiring.

The silent Struggle: Unraveling the Complexities of Rectal Cancer with Leading Oncologist dr. Anya Sharma

Did you know that rectal cancer,while less prevalent than colon cancer,presents unique challenges in diagnosis and treatment that frequently enough lead to prolonged battles for patients like Fourten Ary Admaja Sinaga? Let’s delve into this critical health issue with Dr. Anya Sharma, a leading oncologist specializing in colorectal cancers.

Senior Editor (SE): Dr. Sharma, Mr. Sinaga’s case highlights a prolonged and arduous fight against stage 3B rectal cancer. Can you explain the specific difficulties associated with this advanced stage?

Dr. Sharma (DS): Stage 3B rectal cancer signifies that the cancerous cells have metastasized to nearby lymph nodes,considerably complicating complete surgical resection. This advanced stage often necessitates a multimodal approach, expertly combining surgical intervention, chemotherapy, and radiotherapy. The rectum’s proximity to crucial structures such as the bladder and nerves adds a layer of meaningful complexity to surgical procedures, increasing the risk of complications including bowel incontinence or sexual dysfunction. Treatment strategies are highly personalized, carefully considering the patient’s overall health, the unique characteristics of the tumor itself, and the response observed during each phase of therapy. Treatment planning for rectal cancer at this stage is a truly nuanced and detailed undertaking.

SE: The article details Mr. Sinaga’s experiance with various treatment regimens, including chemotherapy and radiotherapy; yet, the tumor persisted. Why might these treatments prove ineffective in some instances?

DS: Sadly, not all cancers respond equally to standard treatment protocols. Tumor heterogeneity—the diversity in the genetic makeup and behavior of cancer cells within a single tumor—contributes substantially to treatment resistance. Some cancer cells may inherently resist chemotherapy drugs or radiation,enabling them to continue proliferating while others are eradicated. The presence of tumor adhesions, as noted in mr. Sinaga’s case, further impedes treatment effectiveness. These adhesions essentially bind the tumor to surrounding tissues, making complete surgical removal incredibly challenging and hindering the penetration of chemotherapy drugs. Advanced stages often involve subclinical or microscopic disease spread; therefore,prolonged and consistent treatment is often a necessity.

SE: Mr.Sinaga experienced substantial weight loss, a common symptom associated with cancer. what are the primary mechanisms through which cancer induces weight loss, and what should individuals be aware of?

DS: Unintended weight loss in cancer patients is a multifaceted problem with several contributing factors. Cancer cells aggressively compete with healthy cells for essential nutrients, leading to malnutrition. This is frequently exacerbated by the side effects of treatments like chemotherapy and radiotherapy,which can suppress appetite and disrupt the digestive system. Moreover, the tumor’s production of pro-inflammatory substances, along with disease-induced metabolic shifts, significantly contributes to weight loss. Individuals should remain vigilant about any unexplained weight loss, especially if accompanied by other symptoms such as persistent fatigue, altered bowel habits, or ongoing abdominal discomfort. Immediate medical evaluation is essential in determining the root cause.

SE: The article mentions a potential genetic predisposition, given Mr. Sinaga’s father’s history of gastric cancer.How significant is family history in assessing an individual’s risk for rectal cancer?

DS: A family history of cancer, especially colorectal cancers, significantly elevates the risk of developing the disease.While not a certainty, it strongly suggests a hereditary predisposition.Genetic testing can reveal specific gene mutations that indicate an increased likelihood of developing certain cancers. Understanding your family’s medical history is a crucial preventive measure. Individuals with a family history should undergo early detection screening, such as colonoscopies, more frequently and at an earlier age.

SE: What are some key preventive measures individuals can take to reduce their colorectal cancer risk?

DS: prevention is key. Here are some crucial steps:

Maintain a healthy lifestyle: A diet abundant in fruits, vegetables, and fiber, combined with regular physical activity, is paramount.

Limit red and processed meat consumption: These are linked to an increased cancer risk.

Avoid smoking and excessive alcohol consumption: Both significantly increase cancer risk.

Adhere to recommended screening guidelines: Screening should begin at age 45 or earlier if a family history exists.

* Know your family medical history: Discuss cancer history with your doctor for a comprehensive risk assessment.

SE: What is the outlook for patients diagnosed with stage 3B rectal cancer?

DS: The prognosis for stage 3B rectal cancer is variable and depends on numerous individual factors. Improvements in treatment strategies, including advanced chemotherapy regimens and targeted therapies, have significantly enhanced outcomes. While it remains a serious condition, early detection and diligent adherence to treatment protocols are crucial for better long-term survival rates. Ongoing post-treatment monitoring is also essential for promptly detecting any recurrence. Remember, this information is for general knowledge and should not replace professional medical advice.

SE: In closing, what key takeaways would you like to leave our readers with regarding rectal cancer?

DS: Mr. Sinaga’s story underscores the importance of early detection, advanced treatment options, and the invaluable support systems crucial for patients grappling with this disease. The resilience demonstrated by individuals and their families facing this challenge is truly inspiring. Early detection truly saves lives, and proactive preventive measures alongside regular screening are incredibly vital to combat this disease.

what are your thoughts on Mr. Sinaga’s story, and what questions do you have about rectal cancer prevention and treatment? Share your insights in the comments below!

March 1, 2025 0 comments

Health

FDA proposes removal of common decongestant

by Chief editor of world-today-news.com December 2, 2024

written by Chief editor of world-today-news.com

Popular Cold Remedy Ingredient Faces the Axe as FDA Questions Its Effectiveness

Huntington, WV – In a move that could shake up the over-the-counter cold and flu aisle, the U.S. Food and Drug Administration has proposed removing a common decongestant ingredient from many medications. Phenylephrine, found in products like Vicks Dayquil and Mucinex Sinus Max, has long been a go-to for stuffy noses and sinus pressure. But the FDA now says evidence suggests it simply doesn’t work.

"Phenylephrine is an oral decongestant and vasoconstrictor," explains Valley Health Pharmacist Dr. Aaron Stone. "By that, it means it tightens up the blood vessels and by doing that it will hopefully clear up some sinus issues.”

However, the FDA’s recent research casts doubt on these claims.

“The FDA is there to ensure that products are effective and safe," notes Stone. "The study shows it’s not necessarily effective. That’s one reason some may say to get rid of it. In terms of safety, phenylephrine is a decongestant and a vasoconstrictor, meaning it can tighten up blood vessels. This can be harmful for someone who has uncontrolled high blood pressure.”

The agency’s proposal has launched a six-month public comment period. If finalized, it will result in a significant shift in the cold and flu medication landscape. Many pharmacies are already anticipating the change and have proactively removed phenylephrine-containing products from their shelves.

"A positive side we can look at is less confusion due to fewer choices, because if you look at the cough and cold aisle, you’ll see 20-30 different things,” says Stone, referencing the often-overwhelming array of options facing consumers.

For those seeking relief from cold and sinus symptoms, Stone suggests exploring alternatives like pseudoephedrine, which, due to its potential for misuse, requires a state-issued ID to purchase.

The FDA’s decision reflects a growing trend of scrutinizing common ingredients and demanding scientific evidence for their efficacy and safety. For consumers, this means staying informed and consulting with healthcare professionals to make the best choices for their health.

December 2, 2024 0 comments

Technology

vivo launches X200 Series, continuing the iconic legend The starting price is 29,999 baht.

by Chief editor of world-today-news.com December 2, 2024

written by Chief editor of world-today-news.com

vivo Ditches Traditional Chips, Unveils Dual-Force X200 Series with Industry-First Battery Tech

Miami, FL – October 26, 2024 – Vivo is shaking things up in the tech world with its new X200 series, featuring not one, but two chipsets for an unprecedented mobile experience. The Chinese tech giant, known for its innovative design and powerful features, is launching the X200 and X200 Pro on December 4th, boasting groundbreaking battery technology and a stunning new display.

At the heart of the X200 series lies a unique combination of power. Vivo has ditched the single flagship chip design and opted for a dual-chipset setup, pairing the MediaTek Dimensity 9400 processor with a custom V3+ image processing chip, and rounding it out with the intriguing "BlueChip" technology.

"This innovative dual-chip system allows the phones to achieve better performance while also being 30% more energy-efficient," stated a Vivo representative. "We wanted to push the boundaries of what’s possible in mobile technology, and we believe this is a significant leap forward."

Complementing the dual-chip powerhouse is a stunning display. Both the X200 and X200 Pro feature a vibrant 120Hz screen with a peak brightness of 4500 nits, ensuring crystal clear visuals even in bright sunlight, all while boasting eye-protecting Full Range Luminance 2160Hz PWM Dimming technology.

But Vivo’s innovation doesn’t stop at the processing power and display. The series introduces the industry’s first 3rd generation Silicon Anode "BlueVolt" battery. This exceptional battery technology utilizes semi-solid technology, resulting in an ultra-thin design with increased capacity.

"This revolutionary battery technology allows for extended usage even in extremely cold temperatures, down to -20°C," a Vivo spokesperson explained.

The X200 packs a massive 5800mAh battery, while the X200 Pro boasts an even larger 6000mAh capacity, with 90W super-fast charging and 30W wireless charging capabilities.

Vivo is also ensuring its flagship products are built for endurance. The X200 Pro, featuring their proprietary Armor Glass screen, is 11 times more resistant to drops and shocks compared to its predecessor.

Both models run on the latest Android 15 operating system, personalized with Vivo’s Funtouch OS 15, offering a plethora of customization options and intelligent AI features.

The X200 series will come in luxurious color tones. The X200 Pro will be available in Midnight Black and Titanium Grey, while the standard X200 boasts Aurora Green, Ocean Blue, and Midnight Black options.

Pricing and Availability:

The X200 series will be officially available starting December 4th, 2024. Pre-orders begin today and run until December 3rd.

vivo X200: 12GB + 256GB – $799
vivo X200 Pro: 16GB + 512GB – $999

Pre-order customers will receive a range of exclusive benefits, including extended warranties, premium cases, wireless earphones, and discounts on other Vivo products. More details about these pre-order bonuses can be found on the official Vivo website.

December 2, 2024 0 comments

News

Driving while oral sex ends in Hit and Run, student becomes suspect

by Chief editor of world-today-news.com November 16, 2024

written by Chief editor of world-today-news.com

Jakarta –

The police named a student with the initials MAT (20) as a suspect hit and run case who killed Santoso (45) on Jalan Padjajaran or North Ring Road, Mlati, Sleman, Yogyakarta. The police said that the cause of the accident was because the person who committed the crime was having sex in the car.

“This MAT is using an Xpander vehicle, from Jalan Magelang to the north (then) through Jombor roundabout (to) to the east leading to the slow lane. Here the person under suspect MAT and his accomplice with the initials N,” said Traffic Chief for Sleman Police, AKP Fikri Kurniawan, as reported by detikYogaSaturday (16/11/2024).

Fikri explained that MAT was in the car with his female friend with the initials N. Fikri revealed that the two of them were having sexual activity in the car, which caused MAT to lose focus while driving. .

SEVENTEEN

CHECK TO CONTINUE WITH INDEX

“Inside (the car) they did oral sex that disturbed the driver’s concentration, which was done from Jombor to before they put the UPN intersection on that road,” he said.

Based on the results of the investigation, it was said that the suspect knew that he hit someone. However, the suspect continued to drive and did not help the victim.

“At the time of the accident, the suspect was aware but did not stop or help the victim of this accident,” he said.

It is known that this case started with the discovery of the body of an unknown man who was found lying on the side of Jalan Padjadjaran or North Ring Road, Kapanewon Mlati, Sleman, on Thursday (14/11). When the body was found, there were wounds on the legs and head.

Read the full details at here.

(zap/dhn)

2024-11-16 08:22:00

#Driving #oral #sex #ends #Hit #Run #student #suspect

November 16, 2024 0 comments

Technology

vivo launches OriginOS 5 with faster speeds, AI features, and more

by Chief editor of world-today-news.com October 11, 2024

written by Chief editor of world-today-news.com

vivo and iQOO are preparing to release Android 15 Beta to their smartphones in some models soon Today, the brand has published information about OriginOS 5. What else will it be? We’ll see!

On OriginOS 5, it comes with 15% faster usage speed when opening the app for the first time. And up to 30% faster when switching between apps. It also reduces CPU usage by up to 26%.

vivo launches OriginOS 5 with faster speeds, AI features, and more

OriginOS 5 allows us to customize the lock screen by adding controls and widgets

The important thing in this new OS is AI that comes into play. And it is also the center of OriginOS 5, named “Blue Heart Little V Assistant” which will be the name of vivo’s “Circle to search” feature.

We can also create virtual albums with photos, videos, published articles, links, and more organized into sections. “Memory pieces” that are based on our activity and travel to preserve important moments

There’s also a new Dynamic Island that appears as a card at the top of the screen when you copy content, with contextual AI automatically linking that content to related actions.

In communication, it can also interpret sign language and communicate using virtual human avatars.

For use in cars, Little V can also work as a navigator. which will be connected to the system inside the car Allows you to answer calls and send messages. And the system will automatically handle phone calls and summarize the information for us.

Finally, Little V is also available for Windows, Mac and as an online version. So that we can transfer files on our smartphones to different systems. Calmly and gently

OriginOS 5 is preparing to be released to vivo flagship products like the new X Series and iQOO Series soon, as for older models. We will wait for the update within 2025. However, this is the release schedule for the Chinese model, but Global will have to wait.

Source: GSMArena, oral

October 11, 2024 0 comments

Newer Posts

Older Posts